表紙
市場調查報告書

慢性阻塞性肺病(COPD)治療藥的全球市場 - 產業洞察,趨勢,預測,市場機會分析 2019年∼2026年

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 - 2026

出版商 Coherent Market Insights 商品編碼 865108
出版日期 內容資訊 英文 178 Pages
商品交期: 2-3個工作天內
價格
慢性阻塞性肺病(COPD)治療藥的全球市場 - 產業洞察,趨勢,預測,市場機會分析 2019年∼2026年 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 - 2026
出版日期: 2019年05月27日內容資訊: 英文 178 Pages
簡介

慢性阻塞性肺病(COPD)相關啟發活動,及COPD的盛行率上升,新產品的上市等成為全球慢性阻塞性肺病(COPD)治療藥市場的主要成長要素。

本報告提供慢性阻塞性肺病(COPD)治療藥的世界市場調查,市場概要,各醫藥品分類、給藥途徑、流通管道、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場範圍

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各醫藥品分類
    • 市場片段:各給藥途徑
    • 市場片段:各流通管道
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 法規方案
  • 主要的焦點
  • 共同研究開發、合併、收購
  • PEST分析
  • 開發平台分析
  • 流行病學

第4章 慢性阻塞性肺病(COPD)治療藥市場:各醫藥品類型

  • 簡介
  • 支氣管擴張藥
  • PDE4型抑制劑
  • 類固醇
  • 其他

第5章 慢性阻塞性肺病(COPD)治療藥市場:各給藥途徑

  • 簡介
  • 口服給藥
  • 吸入

第6章 慢性阻塞性肺病(COPD)治療藥市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 慢性阻塞性肺病(COPD)治療藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 中南美
  • 非洲
  • 中東

第8章 競爭環境

  • 熱圖分析
  • 企業簡介
    • AstraZeneca Plc
    • Orion Corporation
    • Mylan N.V.
    • Boehringer Ingelheim
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Novartis AG
    • Sunovion Pharmaceuticals, Inc.
    • CHIESI Farmaceutici SpA

第9章 Section

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights
目錄

Chronic obstructive pulmonary disease (COPD) presents itself with mild, moderate, and severe symptoms. Treatment of chronic obstructive pulmonary disease (COPD) involves stepwise non-pharmacological and pharmacological interventions. Non-pharmacological interventions include risk reduction (smoking cessation) and preventing and treating co-morbidities (cardiovascular disease, anxiety, depression, and others). Pharmacological interventions include prescribing short acting bronchodilators, long acting bronchodilators, and others.

Market Dynamics

Factors such as awareness initiatives by organizations, increasing prevalence of COPD, and product launches is supporting the global chronic obstructive pulmonary disease (COPD) treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care announced the creation of a new patient registry, APEX COPD, to better understand COPD and how it can be typically treated in primary care offices. Such initiatives by industry players are expected to boost global chronic obstructive pulmonary disease (COPD) treatment market over the forecast period. Moreover, pipeline for respiratory diseases and mainly COPD has several potential medications, which is expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth.

Key features of the study:

  • This report provides in-depth analysis of global chronic obstructive pulmonary disease (COPD) treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018-2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA
  • Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:

  • Oral
  • Inhalation

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:

North America

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • U.S.
  • Canada

Europe

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

Middle East

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • GCC
  • Israel
  • Rest of Middle East

Africa

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country/Region:

  • Central Africa
  • South Africa
  • North Africa

Company Profiles

  • AstraZeneca Plc*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments
  • Orion Corporation
  • Mylan N.V.
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
  • CHIESI Farmaceutici SpA

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Key Highlights
  • Research and Development Collaboration, Mergers, and Acquisitions
  • PEST Analysis
  • Pipeline Analysis
  • Epidemiology

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
  • Phosphodiesterase Type 4 Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Steroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Inhalation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Regions, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2026
  • North America
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016-2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Orion Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Boehringer Ingelheim
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sunovion Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • CHIESI Farmaceutici SpA
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact